Trial Profile
An investigator initiative trial of STNM01 by an Endoscopic Submocal Injection to Investigate the Efficacy in Patients with Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs STNM 01 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 17 Oct 2023 Results (n=5) assessing efficacy of add-on submucosal injections of GUT-1 presented at the 31st United European Gastroenterology Week
- 12 May 2021 According to a Mitsubishi Tanabe Pharma Corporation media release, MTPC decided to discontinue the STNM01 project as sufficient effects were not confirmed.
- 12 May 2021 Status changed from recruiting to discontinued, according to a Mitsubishi Tanabe Pharma Corporation media release.